Mezzion Pharma, a Seoul, South Korea-based firm growing medical improvement packages, raised roughly $20M USD in strategic funding.
The spherical was led by Midas-Meritz New Expertise Finance Affiliation and KDBC-Korea Funding & Securities New Expertise Funding Affiliation.
The corporate intends to make use of the funds to assist the continuing world Part 3 FUEL-2 trial of udenafil for sufferers with Fontan circulation.
Led by CEO Dean Park, Mezzion Pharma develops therapies for uncommon and underserved illnesses. Its U.S. subsidiary, Mezzion Prescribed drugs, Inc., headquartered in New Jersey, leads world medical improvement and commercialization. The corporate is presently advancing udenafil, a remedy for sufferers with Fontan physiology, a uncommon congenital coronary heart situation, now in world part 3 trials.
FinSMEs
11/06/2025
